PUBLIC COMPANY
saveDelix Therapeutics Inc
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- This week in charts: Brain drugs are back on venture capitalists’ mindsFive neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.biopharma_dive · 23h ago
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 3d ago
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 3d ago
- Neuroplastogen biotech Delix raises $100M Series CDelix Therapeutics has raised $100 million in a Series C to catch up to a budding crop of psychedelics and neuroplastogen drugmakers, cashing in on a new wave of medicines for psychiatric and menta…endpoints · 4d ago
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.fiercebiotech · 5d ago
comments(0)
5-min edit window · permanent after that